Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNxt Solutions Inc BNXTF


Primary Symbol: C.BNXT

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

Recent & Breaking News (CSE:BNXT)

CSE Bulletin: Name and Symbol Change - XPhyto Therapeutics Corp. (XPHY)

Newsfile November 10, 2022

XPhyto Therapeutics Corp. (CSE:XPHY) changes name to BioNxt Solutions Inc.

John Ballem  November 10, 2022

XPhyto Announces Name Change to BioNxt Solutions Inc.

Accesswire November 10, 2022

XPhyto (CSE:XPHY) advancing Parkison's treatment

Caroline Egan  October 18, 2022

XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment

Accesswire October 18, 2022

XPhyto Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study

Accesswire October 11, 2022

XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

Accesswire October 4, 2022

XPhyto Therapeutics (CSE:XPHY) files patent application for library of novel psychedelic compounds

John Ballem  September 20, 2022

XPhyto Files Patent Application for Library of Novel Psychedelic Compounds

Accesswire September 20, 2022

XPhyto Closes Final Tranche of Fully Subscribed Financing

Accesswire September 2, 2022

XPhyto Closes Second Tranche of Financing

Accesswire August 31, 2022

XPhyto Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Accesswire August 2, 2022

XPhyto Therapeutics Announces Offering of Units of the Company

Accesswire July 22, 2022

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Accesswire July 18, 2022

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Accesswire July 15, 2022

Prof. Dr. Raimar Loebenberg Receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

Accesswire June 27, 2022

XPhyto Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to Its European Team

Accesswire June 8, 2022

XPhyto Reports Product Developments on Platform-Based Rotigotine Transdermal Patch for Parkinson's Disease

Accesswire May 9, 2022

XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease

Accesswire April 11, 2022

XPhyto Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease

Accesswire April 4, 2022